Tvardi Therapeutics Inc (TVRD) saw downtrend of -83.92% in the recent trading with $6.69 being its most recent. The current price level -84.67% lower than the highest price of $43.65 marked by the stock while trading over the past 52-weeks, whereas it is -17.66% higher than the lowest price of $8.13 the company dropped to over past 52-weeks. The latest news story on TVRD appeared in (Business Wire) under the title “Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis” on.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.12 for the stock.
Tvardi Therapeutics Inc Earnings – What Happened With TVRD
Coming around sales and income figures on TVRD Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
TVRD – Tvardi Therapeutics Inc Stock Earnings Estimates
The perspective of Tvardi Therapeutics Inc (NASDAQ:TVRD)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.39 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was 0.51.
Tvardi Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 9.37 million. TVRD does have institutional investors; and they hold 20.79% of the stock.
Key Metrics for TVRD
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Tvardi Therapeutics Inc has a debt to equity ratio of 0.01.
